RESTON, Va., Jan. 27, 2016 /PRNewswire/ -- Leidos (NYSE: LDOS), a national security, health, and engineering solutions company, was awarded a task order by the National Institutes of Health (NIH) to provide software development and technical support to the NIH Center for Scientific Review (CSR). The single-award firm fixed-price follow-on contract has a six-month base period of performance, nine six-month options, and a total contract value of $17 million if all options are exercised. Work will be performed in Bethesda, Md.
The CSR is the gateway for NIH grant applications and their review for scientific merit, and is responsible for organizing the peer review groups or study sections that evaluate the majority of the research grant applications sent to NIH. Under the contract, Leidos will provide software development and technical support including developing and maintaining various web-based, desktop and mobile-based applications in support of CSR's primary mission of scientific peer review. Leidos will also provide technical support for both on premise and remote network access areas, including the installation, configuration, testing and maintenance of hardware and software.
"We are honored to continue supporting the CSR with technical excellence to provide an efficient and cost-effective peer review process, better infrastructure controls and expanded collaboration," said Jerry Hogge, Deputy Group President, Leidos Health.
About Leidos Leidos is a science and technology solutions leader working to address some of the world's toughest challenges in national security, health and engineering. The Company's 19,000 employees support vital missions for government and the commercial sector, develop innovative solutions to drive better outcomes and defend our digital and physical infrastructure from 'new world' threats. Headquartered in Reston, Virginia, Leidos reported annual revenues of approximately $5.06 billion for its fiscal year ended January 30, 2015. For more information, visit www.Leidos.com.
Statements in this announcement, other than historical data and information, constitute forward-looking statements that involve risks and uncertainties. A number of factors could cause our actual results, performance, achievements, or industry results to be very different from the results, performance, or achievements expressed or implied by such forward-looking statements. Some of these factors include, but are not limited to, the risk factors set forth in the company's Annual Report on Form 10-K for the period ended January 30, 2015, and other such filings that Leidos makes with the SEC from time to time. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof.